Floatz logo

HYDROMORPHONE HYDROCHLORIDE CII

Perioperative/Postoperative Complications

University of California, San FranciscoSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Perioperative/Postoperative Complications cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Copenhagen University Hospital, Hvidovre
Phase 4BB
FLUOROURACILUM
Cambridge University Hospitals NHS Foundation Trust
Phase 3B
Docetaxel
Cambridge University Hospitals NHS Foundation Trust
Phase 3B
Irinotecan
Cambridge University Hospitals NHS Foundation Trust
Phase 3B
Tislelizumab
Cambridge University Hospitals NHS Foundation Trust
Phase 3B

View all 14 →

Same molecule, other indications

HYDROMORPHONE HYDROCHLORIDE CII is also rated in:

Multimodal AnalgesiaDormant
BB
Indicative ·
69 / 100
View asset →
Real-world StudyDormant
BB
Indicative ·
69 / 100
View asset →
Enhanced Recovery After SurgeryDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →